Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim). When considering the Amgen Inc stock dividend history, we have taken known splits into account, such that the AMGN dividend history is presented on a split-adjusted ("apples to apples") basis. Amgen Inc dividend history is presented both in graphical/chart form, and as a AMGN dividend history data table along the right-hand column.
|
AMGN Stock Dividend HistoryThe AMGN dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable AMGN historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the AMGN dividend history record. Also see the AMGN stock dividend history data table along the right-hand column below. |
|
AMGN Next Dividend Date » (Projection based upon history) AMGN Dividend Growth Rate » Quotes delayed 20 minutes |
Buy (2.68 out of 4) 19th percentile
(ranked lower than approx. 81% of all stocks covered)
Analysts' Target Price: AMGN Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: AMGN Next Dividend Date Chart: AMGN Chart - 5Yr Dividend Yield |